clinical trial · NCT07522151
Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer
Shanghai Shengdi Pharmaceutical Co., Ltd·phase3·not yet recruiting·n = 874
Locally Advanced Gastric or Gastroesophageal Junction CancerAdebrelimab plus S-1 and oxaliplatinAdebrelimab blank preparation plus S-1 and oxaliplatin.
brief summary
This study was a randomized, double-blind, multi-center phase III clinical trial to evaluate the event-free survival (EFS) of Adebrelimab with S-1 and oxaliplatin versus placebo combined with S-1 and oxaliplatin, and to evaluate the efficacy, safety and tolerability of the two combination regimens.
started
May 1, 2026
primary completion
Dec 1, 2029
completion
Feb 1, 2034
last updated
Apr 13, 2026
official title
A Randomized, Double-blind, Multicenter Phase III Trial of Adebrelimab (SHR-1316) Plus S-1 and Oxaliplatin (SOX) Versus Placebo Plus S-1 and Oxaliplatin in the Perioperative Treatment of Resectable Gastric or Gastroesophageal Junction Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol